

Analysis of Gene Expression in Normal and Tumor Liver Tissue

A Comparison of the Applied Biosystems Expression Array System with a Leading Competitive Platform

Introduction

The Applied Biosystems Expression Array System is equipped with the Applied Biosystems 1700 Chemiluminescent Microarray Analyzer that houses electro-optical systems for fast, sensitive detection of gene expression. In combination with optimized chemiluminescent chemistry kits and microarrays that survey

whole genomes, this system is designed to measure the very low gene expression levels that platforms equipped only with fluorescence detection often miss.

In this study we designed a series of experiments to compare the Applied Biosystems Expression Array System with a leading competitive platform.

The sensitivity of each platform was determined by comparing the number of genes that are detectable and the fold changes in differential gene expression as measured between normal and tumor tissue samples.

System Specifications	Applied Biosystems Expression Array System	Competitive Microarray
Oligo probe length	60-mer	25-mer
Manufacturing method	Spotting with contact technology	<i>In situ</i> photolithography
Dye or detection chemistry	Chemiluminescence with alkaline phosphatase enzyme	Fluorescence with phycoerythrin dye
Genes studied	10,687 cross-mapped common genes between platforms	
Input RNA labeling	1 µg/replicate (Applied Biosystems Chemiluminescent RT-IVT Kit)	4 µg/replicate (recommended RT-IVT Kit)
Data analysis	<ul style="list-style-type: none"> • Gene detection sensitivity • Differential gene expression (normal vs. tumor) 	




Figure 1. Number of detectable genes in both normal and tumor liver tissues. Detection thresholds used for each platform are as follows: Applied Biosystems platform, $S/N > 3$; leading competitive platform, Present/Absent ($p < 0.05$).

Of 10,687 common genes that are cross-mapped between Applied Biosystems Expression Array System and the leading competitive platform, Applied Biosystems platform (blue) detected 2,710 more genes in normal tissue and 2,542 more genes in tumor tissue than the competitive platform (purple).




Figure 2. The reproducibility of the Applied Biosystems Expression Array System was also evaluated using both normal and tumor samples. This figure shows a high degree of correlation in both normal vs. normal and tumor vs. tumor samples. The technical replicates for normal (**A**) and tumor (**B**) samples were plotted as follows:

X axis: $A = 0.5 * \log_2 (\text{Signal_rep1} * \text{Signal_rep2})$; Y axis: $M = \log_2 (\text{Signal_rep1} / \text{Signal_rep2})$.

Only genes detectable in both replicates are shown in the figures, corresponding to chemiluminescent signal/noise ratios that are greater than 3.




Figure 3. Y axis: $M = \log_2(\text{Signal_tumor}/\text{Signal_normal})$; X axis: $A = 0.5 * \log_2(\text{Signal_tumor} * \text{Signal_normal})$. Genes detected in both normal and tumor samples are shown in the M-A plots above. Differentially expressed genes (> 2-fold changes between tumor and normal samples) are shown in red. Blue indicates genes that are changed < 2-fold. **A.** Of the 10,687 cross-mapped common genes analyzed on the Expression Array System, 6,893 genes are present in both the normal and tumor samples and 862 genes have > 2-fold changes. **B.** Of the 10,687 common genes analyzed on the competitive platform, 4,464 genes are present in both normal and tumor samples, and 336 genes have > 2-fold changes.




Figure 4. Cross-mapping studies between the Applied Biosystems Human Genome Survey Microarray and the competitive microarray revealed that of the 27,868 genes targeted by the Applied Biosystems microarray, 7,142 genes are not represented on the competitive microarray. Of these unique genes, 3,643 and 3,700 were detected in normal and tumor samples, respectively. The concordance between these tissues (i.e. genes in common) was 3,172 genes of which 337 exhibited > 2 fold changes (red).




Figure 5. Two-dimensional hierarchical clustering analysis was performed on the Applied Biosystems Expression Array System data set using GeneSpring™ Software. The cluster diagram above shows 1,569 expressed genes (of the 27,868 genes represented on the Applied Biosystems microarray) that were determined to have more than 2-fold differential expression between tissues. In this analysis the genes were identified from an ANOVA analysis of 4 tumor and 4 normal samples with a predicted false discovery rate of < 5% (Benjamini Hochlag multiple testing). Red and blue represent high and low gene expression levels respectively, and yellow represents no, or unchanged expression levels.

Of the 1,569 differentially expressed genes identified by the Applied Biosystems Expression Array System, 1,292 genes (82%) were identified solely by the Expression Array System, and 277 genes (18%) were identified by both platforms. Within these 1,292 genes, 1,102 genes (70%) were identified from the cross-mapped, common genes and 190 genes (12%) were Applied Biosystems unique genes.

Conclusions

- From the 10,687 cross-mapped genes in common, the Applied Biosystems Expression Array System detects 2,710 more genes in normal tissue, and 2,542 more genes in tumor tissue than the leading competitive platform
- The Applied Biosystems Human Genome Survey Microarray contains > 7,142 more genes than the competitors microarray and, therefore, is able to provide more comprehensive gene coverage. Among these additional genes, 3,643 and 3,700 genes were detectable in normal and tumor tissues respectively
- Because the Applied Biosystems Expression Array System consumed less input total RNA than the competitive system, we infer superior detection sensitivity.



iScience. To better understand the complex interaction of biological systems, life scientists are developing revolutionary approaches to discovery that unite technology, informatics, and traditional laboratory research. In partnership with our customers, Applied Biosystems provides the innovative products, services, and knowledge resources that make this new, **Integrated Science** possible.

Worldwide Sales Offices

Applied Biosystems vast distribution and service network, composed of highly trained support and applications personnel, reaches 150 countries on six continents. For international office locations, please call the division headquarters or refer to our Web site at www.appliedbiosystems.com

Applera is committed to providing the world's leading technology and information for life scientists. Applera Corporation consists of the Applied Biosystems and Celera Genomics businesses.

Headquarters

850 Lincoln Centre Drive
Foster City, CA 94404 USA
Phone: 650.638.5800
Toll Free: 800.345.5224
Fax: 650.638.5884

For Research Use Only.
Not for use in diagnostic procedures.

Applied Biosystems and its design are registered trademarks and AB (Design), Applera, iScience, and iScience (Design) are trademarks of Applera Corporation or its subsidiaries in the US and/or certain other countries.

TaqMan is a registered trademark of Roche Molecular Systems, Inc.

GeneSpring is a trademark of Silicon Genetics.

The PCR process and 5' nuclease process are covered by patents owned by Roche Molecular Systems, Inc. and F. Hoffmann-La Roche Ltd.

©2004 Applied Biosystems. All rights reserved.

Printed in the USA, 07/04
P+s, Publication 130DA01-01